IKT

Inhibikase Therapeutics, Inc. [IKT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

IKT Stock Summary

Top 10 Correlated ETFs

IKT


Top 10 Correlated Stocks

IKT


In the News

10:56 29 Mar 2024 IKT

Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now

Inhibikase Therapeutics, Inc. (IKT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

07:51 29 Mar 2024 IKT

New Strong Buy Stocks for February 13th

IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.

11:01 29 Mar 2024 IKT

Best Momentum Stocks to Buy for February 8th

POST, IKT and ACMR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 8, 2023.

07:41 29 Mar 2024 IKT

New Strong Buy Stocks for February 8th

IKT, POST, ASAN, ACMR and HENKY have been added to the Zacks Rank #1 (Strong Buy) List on February 8, 2023.

10:01 29 Mar 2024 IKT

New Strong Buy Stocks for February 6th

EGO, SBSI, CCS, TCBX and IKT have been added to the Zacks Rank #1 (Strong Buy) List on February 6, 2023.

07:05 29 Mar 2024 IKT

New Strong Buy Stocks for January 31st

ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.

11:01 29 Mar 2024 IKT

Best Momentum Stocks to Buy for January 26th

PCAR, IKT and PD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 26, 2023.

07:26 29 Mar 2024 IKT

New Strong Buy Stocks for January 26th

IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.

01:00 29 Mar 2024 IKT

Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?

Inhibikase Therapeutics, Inc. (IKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

05:38 29 Mar 2024 IKT

Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript

Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q3 2023 Earnings Conference Call November 15, 2023 8:00 AM ET Company Participants Alex Lobo - IR Milton Werner - CEO Joseph Frattaroli - CFO Conference Call Participants Edward White - H.C. Wainwright Operator Hello, and welcome to the Inhibikase Therapeutics Third Quarter 2023 Financial Results.

IKT Financial details

Company Rating
Sell
Market Cap
13.8M
Income
-18.54M
Revenue
383.94K
Book val./share
2.81
Cash/share
3.15
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
29 Mar 2024
P/E
-0.4
Forward P/E
-1.45
PEG
0.19
P/S
22.35
P/B
0.49
P/C
0.69
P/FCF
-0.48
Quick Ratio
6.14
Current Ratio
6.4
Debt / Equity
0.02
LT Debt / Equity
0.01
-
-
EPS (TTM)
-3.83
EPS next Y
-1.49
EPS next Q
-0.79
EPS this Y
-12.7%
EPS next Y
-61.1%
EPS next 5Y
-93.99%
EPS last 5Y
21.48%
Revenue last 5Y
-50.23%
Revenue Q/Q
-31.65%
EPS Q/Q
-22.52%
-
-
-
-
SMA20
-2.27%
SMA50
41.45%
SMA100
138.89%
Inst Own
0.05%
Inst Trans
0%
ROA
-104%
ROE
-92%
ROC
-1.32%
Gross Margin
100%
Oper. Margin
-5215%
Profit Margin
-4830%
Payout
-
Shs Outstand
6.19M
Shs Float
5M
-
-
-
-
Target Price
-
52W Range
0.79-4.92
52W High
-
52W Low
-
RSI
46.72
Rel Volume
0.63
Avg Volume
151.82K
Volume
96.11K
Perf Week
11.92%
Perf Month
-14.96%
Perf Quarter
140%
Perf Half Y
56.52%
-
-
-
-
Beta
1.196
-
-
Volatility
0.08%, 0.12%
Prev Close
-6.09%
Price
2.16
Change
-4.42%

IKT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
3.030.820.511.020.03
Net income per share
-1.61-4.22-2.1-4.88-4.26
Operating cash flow per share
0.54-0.25-0.83-4.71-4.13
Free cash flow per share
0.54-0.25-0.83-4.71-4.19
Cash per share
0.280.0110.1913.435.49
Book value per share
-0.58-3.297.1512.665.01
Tangible book value per share
-0.58-3.297.1512.665.01
Share holders equity per share
-0.58-3.297.1512.665.01
Interest debt per share
0.20.290.250.090.1
Market cap
79.34M80.99M56.67M26.77M12.61M
Enterprise value
79.19M81.35M43.03M-13.73M5.77M
P/E ratio
-36.86-14.09-19.69-1.81-0.7
Price to sales ratio
19.6372.1481.138.63102.12
POCF ratio
110.96-239.41-50.18-1.87-0.73
PFCF ratio
110.96-239.41-50.18-1.87-0.72
P/B Ratio
-101.98-18.045.790.70.6
PTB ratio
-101.98-18.045.790.70.6
EV to sales
19.672.4561.61-4.4346.73
Enterprise value over EBITDA
-37.32-14.28-15.270.93-0.32
EV to operating cash flow
110.76-240.46-38.10.96-0.33
EV to free cash flow
110.76-240.46-38.10.96-0.33
Earnings yield
-0.03-0.07-0.05-0.55-1.42
Free cash flow yield
0.010-0.02-0.53-1.4
Debt to equity
-0.3-0.080.030.010.02
Debt to assets
0.089.770.020.010.01
Net debt to EBITDA
0.07-0.064.842.740.38
Current ratio
0.350.013.1310.476.59
Interest coverage
-69.96-229.44-95.86-741.16-243.49
Income quality
-0.330.060.40.970.96
Dividend Yield
00000
Payout ratio
000-0.010
Sales general and administrative to revenue
0.620000
Research and developement to revenue
0.92.271.283.6697.5
Intangibles to total assets
00000
Capex to operating cash flow
00000.01
Capex to revenue
0000-1.97
Capex to depreciation
0000-36.18
Stock based compensation to revenue
0.161.280.820.493.71
Graham number
4.617.6718.3937.2821.91
ROIC
3.91.39-0.28-0.38-0.83
Return on tangible assets
-0.76-150.25-0.19-0.35-0.72
Graham Net
-2.16-3.316.5412.144.7
Working capital
-2.37M-4.22M10.06M38.42M20.68M
Tangible asset value
-777.97K-4.49M9.78M38.42M21.04M
Net current asset value
-2.37M-4.49M9.78M38.42M20.47M
Invested capital
-0.3-0.080.030.010.02
Average receivables
0236.47K055.07K75.01K
Average payables
0977.97K1.36M1.41M1.12M
Average inventory
00053.5K612.31K
Days sales outstanding
42.720012.97117.92
Days payables outstanding
0143.23702.6735.0262.5K
Days of inventory on hand
0003.4460.68K
Receivables turnover
8.540028.153.1
Payables turnover
02.550.5210.420.01
Inventory turnover
000106.160.01
ROE
2.771.28-0.29-0.39-0.85
Capex per share
0000-0.06

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.030.010.020.01
Net income per share
-1.06-0.99-0.87-1.11-0.86
Operating cash flow per share
-1.31-0.85-1.3-0.87-0.77
Free cash flow per share
-1.36-0.8-1.3-0.88-0.77
Cash per share
6.315.495.614.013.15
Book value per share
5.985.015.523.722.81
Tangible book value per share
5.985.015.523.722.81
Share holders equity per share
5.985.015.523.722.81
Interest debt per share
0.090.10.120.140.05
Market cap
22.96M12.59M18.11M18.87M7.43M
Enterprise value
17.55M5.76M14.48M17.26M-7.17M
P/E ratio
-1.29-0.76-1.13-0.82-0.4
Price to sales ratio
3.15K102.02280.7162.0793.33
POCF ratio
-4.17-3.54-3.03-4.13-1.81
PFCF ratio
-4.02-3.75-3.03-4.12-1.81
P/B Ratio
0.910.60.720.970.49
PTB ratio
0.910.60.720.970.49
EV to sales
2.41K46.63224.41148.26-90.05
Enterprise value over EBITDA
-3.9-1.32-3.07-2.861.5
EV to operating cash flow
-3.19-1.62-2.42-3.781.75
EV to free cash flow
-3.08-1.72-2.42-3.771.75
Earnings yield
-0.19-0.33-0.22-0.31-0.62
Free cash flow yield
-0.25-0.27-0.33-0.24-0.55
Debt to equity
0.010.020.010.020.02
Debt to assets
0.010.010.010.010.02
Net debt to EBITDA
1.21.570.770.273.06
Current ratio
8.716.5910.378.046.4
Interest coverage
-243.48-77.53-19.88-14.610
Income quality
1.220.831.330.790.89
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
408.9524.7444.2438.9640.54
Intangibles to total assets
00000
Capex to operating cash flow
0.04-0.06000
Capex to revenue
-27.451.620-0.120
Capex to depreciation
-119.0839.70-0.090
Stock based compensation to revenue
13.960.811.911.071.63
Graham number
11.9410.5810.429.637.38
ROIC
-0.17-0.19-0.16-0.31-0.31
Return on tangible assets
-0.16-0.17-0.14-0.26-0.26
Graham Net
5.64.75.13.512.61
Working capital
24.77M20.68M24.96M19.25M14.81M
Tangible asset value
25.14M21.04M25.32M19.46M15.02M
Net current asset value
24.54M20.47M24.79M19.1M14.69M
Invested capital
0.010.020.010.020.02
Average receivables
10.2K26.86K52.2K72.06K39.8K
Average payables
820.83K966.2K1.06M856.61K744.35K
Average inventory
925.74K1.03M1.02M674.18K212.61K
Days sales outstanding
170.8729.089061.540
Days payables outstanding
41.83K20.55K17.12K426.3310.07K
Days of inventory on hand
49.92K19.95K16.47K240.390
Receivables turnover
0.533.111.460
Payables turnover
000.010.210.01
Inventory turnover
000.010.370
ROE
-0.18-0.2-0.16-0.3-0.31
Capex per share
-0.050.05000

IKT Frequently Asked Questions

What is Inhibikase Therapeutics, Inc. stock symbol ?

Inhibikase Therapeutics, Inc. is a US stock , located in Atlanta of Ga and trading under the symbol IKT

What is Inhibikase Therapeutics, Inc. stock quote today ?

Inhibikase Therapeutics, Inc. stock price is $2.16 today.

Is Inhibikase Therapeutics, Inc. stock public?

Yes, Inhibikase Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap